Results 111 to 120 of about 12,272 (217)

Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.

PLoS ONE, 2017
More than 60% of myeloid dysplasia syndrome (MDS) contains mutations in genes encoding for splicing factors such as SF3B1, U2AF, SRSF2 and ZRSR2. Mutations in SF3B1 are associated with 80% cases of refractory anemia with ring sideroblast (RARS), a ...
Shuiling Jin, Hairui Su, Ngoc-Tung Tran, Jing Song, Sydney S Lu, Ying Li, Suming Huang, Omar Abdel-Wahab, Yanyan Liu, Xinyang Zhao   +9 more
doaj   +1 more source

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts

, 2015
Refractory anemia with ring sideroblasts (RARS) is a myelodysplastic syndrome (MDS) characterized by isolated erythroid dysplasia and 15% or more bone marrow ring sideroblasts.
DELLA PORTA, MATTEO GIOVANNI, Ambaglio I, Karimi M, Campbell PJ, Pietra D, MALCOVATI, LUCA, Travaglino E, Papaemmanuil E, INVERNIZZI, ROSANGELA, Conte S, ELENA, CHIARA, Rosenquist R, Hellström Lindberg E., Jansson M, CAZZOLA, MARIO, Walldin G, Boveri E, Gallì A, Ljungström V, Kallenbach K, Jädersten M, Raaschou Jensen K   +21 more
core   +2 more sources

Acute Myeloid Leukemia With Florid Plasmacytoid Dendritic Cell Expansion and Aberrant Expression of CD19

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 919-920, October 2026.
Afshin Shameli, Russell K. Dorer
wiley   +1 more source

Inclusion of Multi‐Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High‐Intensity Induction Chemotherapy

Cancer Medicine, Volume 15, Issue 9, September 2026.
ABSTRACT Background Despite advancements in genetic markers for acute myeloid leukemia (AML) risk stratification, outcome prediction remains challenging due to disease heterogeneity and dynamic genetic changes, highlighting the need for reliable biomarkers to improve AML treatment strategies and patient outcomes.
Samantha Franklin, Pranoti Sahasrabhojane, Ivan Ivanov, Tomo Hayase, Eiko Hayase, Chia‐Chi Chang, Jayastu Senapati, Sai Prasad Desikan, Tapan Kadia, Phillip Lorenzi, Robert R. Jenq, Samuel Shelburne, Jessica Galloway‐Peña   +12 more
wiley   +1 more source

Severe Macrocytic Anemia Associated With a Novel ALAS2 Mutation: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 9, September 2026.
ABSTRACT X‐linked sideroblastic anemia (XLSA), caused by pathogenic variants in ALAS2, typically presents as microcytic anemia in males. However, heterozygous females occasionally exhibit an atypical macrocytic phenotype, often leading to diagnostic ambiguity and confusion with nutritional anemias or myelodysplastic syndromes.
Haodong Cai, Kefeng Shen, Jin Wang, Jia Gu, Meilan Zhang, Min Xiao   +5 more
wiley   +1 more source

Deciphering the role of SF3B1 in hematopoiesis

, 2017
Hematologic malignancies claim the lives of many people every year, yet we lack a complete understanding of the mechanisms of pathogenesis behind them. Myelodysplastic Syndromes (MDS) are a group of hematologic malignancies characterized by bone marrow ...
De La Garza Sauceda, Adriana
core  

Inhibition of SF3B1 phosphorylation by DYRK1A in HeLa cells.

, 2015
HeLa cells expressing GFP-SF3B1-NT were treated with the indicated compounds for 18 h. The phosphorylation state of SF3B1 was determined by immunoblotting with pT434 antibody, and the results were normalized to the total amount of SF3B1 immunoreactivity.
Agnes Walte (772754), Anne Wurzlbauer (772753), Katharina Rüben (772752), Wolfgang Sippl (169574), Franz Bracher (458039), Walter Becker (31437)   +5 more
core   +1 more source

Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies

Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Resistance to venetoclax has become a critical bottleneck limiting its long‐term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. Abstract To date, the treatment of acute myeloid leukaemia
Jinlin Zhang, Jile Liu, Mohan Zhao, Xiaoyu Zhang, Linlin Liu, Mengnan Li, Changze Cao, Rui Zhang, Mingfeng Zhao   +8 more
wiley   +1 more source

Splicing factor Sf3b1 facilitates maintenance of neuronal dendrites by modulating mitochondrial health

Cellular and Molecular Life Sciences
The intricate process of dendritic arborization is essential for forming functional neural circuits, and many of the underlying molecular and cellular mechanisms have been uncovered.
Wei-Chia Tsao, Yi-Chun Huang, Hsin-Ho Sung, Chi-Hung Lin, Hwei-Jan Hsu, Hsiu-Fen Lin, Cheng-Ting Chien   +6 more
doaj   +1 more source

Dissecting Bone Marrow Fibrosis in Philadelphia‐Negative Myeloproliferative Neoplasms: Multiple Roads Lead to Rome

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Philadelphia‐negative myeloproliferative neoplasms (MPN), a spectrum of blood malignancies characterized by uncontrolled myeloid proliferation, persist as a key challenge in onco‐hematology due to their intricate molecular background, heterogeneous clinical phenotypes, and variable prognoses.
Mariagiovanna Ballato, Vincenzo Fiorentino, Gabriele Ricciardi, Pietro Tralongo, Emanuela Germanà, Alessandro Allegra, Fabio Stagno, Guido Fadda, Maurizio Martini   +8 more
wiley   +1 more source